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Abstract 
We have previously shown that the adenosine analog 5-aminoimidazole-4-carboxamide-1-β-d-
ribofuranoside (AICAR), an activator of AMP-activated protein kinase (AMPK), stimulates an increase in 
AMPK activity and induces meiotic resumption in mouse oocytes [Downs, S.M., Hudson, E.R., Hardie, 
D.G., 2002. A potential role for AMP-activated protein kinase in meiotic induction in mouse oocytes. 
Dev. Biol, 245, 200–212]. The present study was carried out to better define a causative role for AMPK 
in oocyte meiotic maturation. When microinjected with a constitutively active AMPK, about 20% of 
mouse oocytes maintained in meiotic arrest with dibutyryl cAMP (dbcAMP) were stimulated to 
undergo germinal vesicle breakdown (GVB), while there was no effect of catalytically dead kinase. 
Western blot analysis revealed that germinal vesicle (GV)-stage oocytes cultured in dbcAMP-containing 
medium plus AICAR possessed elevated levels of active AMPK, and this was confirmed by AMPK assays 
using a peptide substrate of AMPK to directly measure AMPK activity. AICAR-induced meiotic 
resumption and AMPK activation were blocked by compound C or adenine 9-beta-d-arabinofuranoside 
(araA, a precursor of araATP), both inhibitors of AMPK. Compound C failed to suppress adenosine 
uptake and phosphorylation, indicating that it did not block AICAR action by preventing its metabolism 
to the AMP analog, ZMP. 2′-Deoxycoformycin (DCF), a potent adenosine deaminase inhibitor, reversed 
the inhibitory effect of adenosine on oocyte maturation by modulating intracellular AMP levels and 
activating AMPK. Rosiglitazone, an anti-diabetic agent, stimulated AMPK activation in oocytes and 
triggered meiotic resumption. In spontaneously maturing oocytes, GVB was preceded by AMPK 
activation and blocked by compound C. Collectively, these results support the proposition that active 
AMPK within mouse oocytes provides a potent meiosis-inducing signal in vitro. 
Introduction 
Mammalian oocytes are arrested in the diplotene stage of the first meiotic prophase soon after 
initiating meiosis. The meiotically arrested oocyte is characterized by a prominent nucleus, termed the 
germinal vesicle (GV), which is maintained throughout the period of oocyte growth. Fully grown 
oocytes within healthy, non-atretic secondary follicles are triggered to resume meiotic maturation in 
response to a preovulatory gonadotropin surge. This process is manifested by germinal vesicle 
breakdown (GVB), a morphological change commonly used to monitor meiosis initiation. 
The mechanism by which oocytes overcome the prophase I meiotic arrest is not well understood. 
Oocytes cultured within their follicles in vitro are maintained in meiotic arrest unless stimulated by 
gonadotropin. When the oocyte is removed from the intrafollicular environment and cultured under 
permissible conditions, maturation occurs spontaneously in the absence of hormone stimulation, 
indicating a dependence on the follicular somatic compartment for maintenance of prophase I arrest. If 
cumulus cell-enclosed oocytes are isolated from follicles and maintained at the GV stage in vitro with 
exogenous inhibitor, meiotic resumption can be elicited by gonadotropin. This phenomenon is 
mediated by the cumulus cells that produce a signal driving the oocyte into meiotic maturation. 
Cyclic adenosine monophosphate (cAMP) plays an important role in the regulation of meiotic 
resumption in oocytes. Agents that elevate cAMP levels, cAMP analogs or factors that prevent 
degradation of intracellular cAMP reversibly suppress oocyte maturation. cAMP prevents GVB through 
the activation of cAMP-dependent protein kinase (PKA). Indeed, mouse oocytes maintained in meiotic 
arrest by elevated cAMP can be induced to resume maturation by microinjection of PKA inhibitors 
(Bornslaeger et al., 1986, Eppig, 1989). In Xenopus oocytes, PKA phosphorylates and inactivates cdc25 
phosphatase, thereby blocking activation of maturation promoting factor (cdc2 kinase) and 
contributing to meiotic arrest (Duckworth et al., 2002). Recently, protein tyrosine phosphatase 
nonreceptor type 13 (PTPN13), a substrate of PKA in both mouse and Xenopus oocytes, has been 
implicated in the regulation of oocyte meiotic resumption (Nedachi and Conti, 2004). 
Oocyte cAMP synthesis and hydrolysis are regulated via adenylyl cyclase and cyclic nucleotide 
phosphodiesterase (PDE), respectively. PDE3A is the predominant PDE isoform expressed in rodent 
oocytes (Shitsukawa et al., 2001, Conti et al., 2002), and its activity is increased prior to oocyte 
maturation (Richard et al., 2001). PDE3A-null female mice are infertile as oocytes are ovulated in the 
immature GV stage (Masciarelli et al., 2004). PDE3A-null oocytes lack cAMP-specific PDE activity, 
contain increased cAMP levels, are persistently maintained in the GV stage in vivo and failed to 
undergo spontaneous maturation in vitro. These data indicate that PDE activity is required for oocyte 
maturation. 
The product of PDE activity and cAMP degradation, 5′-AMP, is a potent stimulator of the stress 
response kinase, AMP-activated protein kinase (AMPK), and has been suggested to have an important 
meiosis induction function via activating AMPK (Downs et al., 2002). AMPK, a serine/threonine kinase, 
composed of an α catalytic subunit and β and γ regulatory subunits, is a pivotal enzyme in the 
regulation of cellular energy charge (Hardie and Hawley, 2001, Hardie, 2004, Kahn et al., 2005). AMPK 
is activated by an upstream kinase, recently identified as the tumor repressor, LKB1 (Hawley et al., 
2003, Woods et al., 2003), via phosphorylation of Thr-172 on the α subunit (Hawley et al., 1996). 
Binding of AMP or ATP to CBS domains on the γ subunit (Scott et al., 2004) regulates the activation 
state of the kinase (reviewed by Hardie and Hawley, 2001, Hardie, 2004). AMP promotes 
phosphorylation, and thereby activation, of AMPK by directly binding to the γ subunit of AMPK and 
changing the conformation of the kinase, making it a better substrate for the upstream kinase (Hawley 
et al., 2002) and a worse substrate for the phosphatase (Davies et al., 1990). By controlling the activity 
and expression of important rate-limiting enzymes of carbohydrate, fat and protein metabolism, AMPK 
regulates the cell energy status through conservation of ATP levels. 
5-Aminoimidazole-4-carboxamide-1-β-d-ribofuranoside (AICAR), an analog of adenosine, is widely used 
to activate AMPK in vitro. After entering cells, it is phosphorylated to form AICA ribotide (ZMP), an 
analog of AMP. ZMP, though less effective than AMP, mimics all the activating effects of AMP in the 
AMPK cascade (Corton et al., 1995). Thus, AICAR provides a means of activating AMPK without 
affecting AMP or ATP levels. 
In a previous study, AICAR was shown to rapidly stimulate GVB in mouse oocytes maintained in meiotic 
arrest with a variety of inhibitors (Downs et al., 2002). AICAR was more potent in denuded oocytes 
(DO) than cumulus cell-enclosed oocytes (CEO), identifying the oocyte as the target of AICAR action. 
Meiotic resumption was also induced by AMP in dbcAMP-arrested oocytes. Therefore, these data were 
consistent with the possibility that activation of AMPK provides a potent meiosis-inducing signal. 
In the present study, we determined if AMPK has a causative role in GVB in mouse oocytes by 
modifying AMPK activity and relating it to meiotic status. Using four different strategies to expose 
oocytes to active AMPK and using two putative inhibitors to block AMPK activity, we show that 
stimulation of AMPK in prophase-I-arrested oocytes leads to meiotic resumption and that preventing 
AMPK activation abolishes the meiotic response. 
Materials and methods 
Oocyte isolation and culture conditions 
C57BL/6JxSJL/J F1 mice, 19–23 days old, were used for all experiments. Mice were primed with 5 IU 
equine choronic gonadotropin and killed 48 h later by cervical dislocation. Ovaries were removed and 
placed in the culture medium, and cumulus cell-enclosed oocytes (CEO) were obtained by puncturing 
large antral follicles with sterile needles. Denuded oocytes were prepared by repeated pipetting with a 
Pasteur pipette. Oocytes were cultured in glass tubes for long-term culture (17–18 h) or in plastic tubes 
for short-term culture (≤4 h). Tubes were gassed with a humidified mixture of 5% CO2, 5% O2 and 90% 
N2 and placed in a water bath at 37°C for the duration of culture. The culture medium used for most 
experiments was Eagle's minimum essential medium with Earle's salts (GIBCO), supplemented with 
0.23 mM pyruvate, penicillin, streptomycin sulfate and 3 mg/ml crystallized lyophilized bovine serum 
albumin (ICN ImmunoBiologicals, Lisle, IL) and buffered with 26 mM bicarbonate. For oocyte 
microinjection, medium was buffered with 25 mM HEPES, pH 7.2, with bicarbonate reduced to 6 mM. 
Microinjection of active/dead AMPK 
To test the effects of microinjected AMPK on oocyte maturation, denuded oocytes were maintained in 
meiotic arrest with 300 μM dbcAMP and microinjected with a preparation of either constitutively 
active AMPK (T172D) or dead (inactive) kinase (D139A), each at a concentration of 7.5 mg/ml. Oocytes 
were placed into a micro-culture dish at room temperature, and approximately 3–10 pl of solution 
containing active or inactivate kinase was injected into the cytoplasm of germinal vesicle-stage oocytes 
using femtotip II needles with an Eppendorf Transjector 5246 system (Eppendorf, Madsion, WI) under 
a Nikon Diaphot 200 inverted microscope equipped with Nomarski optics. Following microinjection, 
oocytes were transferred to 500 μl of dbcAMP-containing medium under mineral oil and placed in a 
37°C incubator for 22 h. A positive control was included in which non-injected oocytes were cultured in 
medium containing dbcAMP plus 250 μM AICAR. At the conclusion of the incubation period, oocytes 
were assessed for GVB. 
Construction and expression of GST-AMPK α1 catalytic domain proteins (T172D, D139A) 
Plasmid DNA encoding GST-tagged AMPK α1 catalytic domain has been previously described (Scott et 
al., 2002). This DNA was used in site-directed mutagenesis (QuickChange, Stratagene) to generate 
constitutively active (T172D) and kinase dead (D139A) GST-tagged AMPK α1 catalytic domain proteins. 
The following synthetic oligonucleotides were used: T172D mutation, GGT GAA TTT TTA AGA GAC AGC 
TGT GGC TCG CCC (sense) and GGG CGA GCC ACA GCT GTC TCT TAA AAA TTC ACC (antisense), D139A 
mutation ATG GTG GTC CAC AGA GCT TTG AAA CCT GAA AAC (sense) and GTT TTC AGG TTT CAA AGC 
TCT TGT GAC CAC CAT (antisense). The underlined bases indicate the sites on the codon where the 
mismatch was placed. All proteins were expressed in E. coli (BL21) and purified on glutathione 
sepharose as previously described (Scott et al., 2002). 
Western blots 
DO and oocyte–cumulus cell complexes (OCC) were washed in phosphate-buffered saline (PBS, pH 
7.4)/PVP (3 mg/ml) plus protease inhibitors (Protease Inhibitors Cocktail Tablets, 1 mM Na 
orthovanadate, 2 μg/ml pepstatin, 50 mM β-Glycerophospate) and then added to an equal volume of 
2× Laemmli's buffer containing 20% β-mercaptoethanol. After heating at 95°C for 5 min, samples were 
stored frozen at −80°C until used for Western blotting. For Western analysis, proteins were 
electrophoresed on a 3–8% Tris–Acetate mini Gel (Invitrogen) for 1 h at 150 V and then transferred to 
nitrocellulose at 100 V for 1 h. To obtain the sharpest bands for active AMPK (PT172) in Fig. 2B, 
samples were electrophoresed on a 4–12% Bis–Tris SDS mini Gel (Invitrogen) for 50 min at 100 V and 
then in a semi-dry system transferred to nitrocellulose at 400 mA for 2.5 h at 4°C. Blots were blocked 
with 5% nonfat milk for 2 h at room temperature and then incubated with primary antibodies (1:250) 
overnight at 4°C, washed in Tris-buffered saline (TBS pH 7.4) 3× 15 min, and incubated with HRP-
conjugated IgG (1:2000) for 1 h at room temperature. Detection was performed with Supersignal 
Western Pico Chemiluminescent Substrate (Pierce; Rockford, IL) and exposed on auto radiographic 
films. Blots were stripped (7 μl/ml BME, 2% SDS, room temperature 30 min) and reprobed with regular 
ACC antiserum (1:2000) as a loading control. Bands were quantified by UVP BioImaging Systems (UVP, 
Inc.; Upland, CA), and ratios of pACC/ACC were presented as the mean of two determinations. 
Anti-pACC was purchased from Upstate Biotechnology Inc. (Lake Placid, NY); anti-ACC antibodies were 
generated in Dr. Hardie's laboratory; anti-PT172 antibody was obtained from Cell Signaling Technology 
(Beverly, MA). 
AMPK assay 
AMPK activity was measured as previously described (Downs et al., 2002, Hardie et al., 2000a, Hardie 
et al., 2000b). Four hundred GV-stage oocytes from each treatment group were collected and washed 
several times in immunoprecipitation (IP) buffer and frozen at −80°C. IP buffer for oocytes contained: 
50 mM Tris–HCl, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NaF, 1 mM Na orthovanodate, 
protease inhibitor cocktail tablet (Roche, Germany), Na pyrophosphate (0.5834 g/250 ml) and 1 mM 
dithiothreitol. 
DNA staining 
After 17–18 h of culture, DO were fixed in 3% formaldehyde in PBS for 0.5–1 h. Oocytes were then 
transferred to a microscope slide and dried on a warming tray. 10 μl glycerol:PBS (1:1) containing 1 
μg/ml Hoechst 3342 (Polysciences, Warrington, PA) was added, and a cover slide was immediately 
placed on the oocytes and sealed with nail polish. Meiotic status was determined using a Leitz Ortholux 
II fluorescent microscope. 
AMP/ATP level measurement 
Denuded oocytes were cultured for varying periods in organ culture dishes containing 1 ml medium. 
After the designated culture times, individual oocytes were assayed for AMP or ATP. 
AMP was assayed as described in Chang et al. (2004). ATP was measured as specified in Chi et al. 
(2002). Briefly, after different treatments, individual oocytes were extracted by 0.5 μl 0.1 N NaOH at 
room temperature for 20 min, 0.5 μl of the extract was heated to 80°C for 20 min, and a 0.2 μl mixture 
of 0.2 N HCl and 0.1 M Tris–HCl (pH 6.8) was added. The NADP+ cycling reagent was used for the ATP 
assay, containing 100 mM imidazole HCl (pH 7.0), 7.5 mM α-ketoglutarate, 5 mM glucose 6-phosphate, 
25 mM NH4Ac, 0.02% BSA, 100 μM ADP, 100 μg/ml beef liver glutamate dehydrogenase and 10 μg/ml 
Leuconostoc mesenteroides glucose 6-phosphate dehydrogenase. The indicator reaction for the NADP+ 
cycling step involves adding 10 μl of the reaction to 1 ml of the indicator, 6-phosphogluconate reagent, 
containing 50 mM imidazole HAc (pH 7.0), 1 mM EDTA, 30 mM NH4Ac, 5 mM MgCl2, 100 μM NADP+ 
and 2 μg/ml yeast 6-phosphogluconate dehydrogenase. 
Statistical analysis 
Oocyte maturation experiments were repeated at least 3 times with at least 25 oocytes per 
experiment. Data are reported as mean percentage GVB ± SEM. Maturation frequencies were 
subjected to arcsin transformation and analyzed statistically by ANOVA followed by Duncan's multiple 
range test. For all statistical analyses, a P value less than 0.05 was considered significant. 
Results 
Microinjection of active AMPK induces oocyte maturation 
To directly determine if active AMPK could stimulate meiotic resumption, bacterially expressed 
constitutively active (T172D) AMPK was injected into meiotically arrested oocytes. Denuded oocytes 
(DO) maintained in meiotic arrest with dbcAMP were microinjected with either a constitutively active 
AMPK or a catalytically inactive (dead) AMPK preparation. DO cultured with AICAR served as a positive 
control. The results of two experiments are shown in Fig. 1. After 21–22 h of culture, AICAR stimulated 
most of the arrested oocytes to resume maturation (94–100% GVB compared to 0–2% of control 
oocytes), indicating the system is responsive to an appropriate meiosis-inducing stimulus. About 20% 
of the oocytes receiving active AMPK were stimulated to undergo maturation. Although this was a 
smaller effect than that of AICAR, the catalytically inactive kinase had no effect. 
 Fig. 1. Microinjection of constitutively active AMPK induces meiotic resumption in dbcAMP-arrested 
oocytes. Oocytes were maintained in meiotic arrest with 300 μM dbcAMP and microinjected with 
either a constitutively active AMPK or a catalytically inactive (dead) AMPK preparation (injection 
volume approximately 3–9 pl). Culture was continued for 20–21 h before assessing GVB. The number 
of oocytes in each group is shown at the top of the bar. 
AMPK is activated prior to GVB in AICAR-treated oocytes 
AICAR, an AMPK activator, is a very potent inducer of oocyte maturation and stimulates AMPK activity 
in mouse oocytes (Downs et al., 2002). To assess the activation state of AMPK on Western blots, two 
different antibodies were used, anti-PT172 and anti-phospho-acetyl CoA carboxylase (Ser-79-pACC). 
Anti-PT172 antibody recognizes phosphorylated Thr-172 on the catalytic subunit and correlates with 
AMPK activity. ACC, an enzyme involved in fatty acid metabolism, is a major substrate of AMPK (Davies 
et al., 1992), and its phosphorylation state on Ser-79 is commonly used as an indirect assay for AMPK 
activity. Extracts were prepared from 230 oocyte–cumulus cell complexes (OCC) cultured for 4 h in 300 
μM dbcAMP plus or minus 1 mM AICAR. Phosphorylation of Thr-172 was evident in freshly isolated 
complexes, but this decreased in intensity after culture, while addition of AICAR to the culture medium 
restored the high level of AMPK activity (Fig. 2A). A similar pattern was seen in the pACC blots. 
 Fig. 2. Western analysis of phosphorylation of AMPK (at pT172) and phosphorylation of ACC (pACC) in 
OCC and DO. (A) Extracts were prepared from freshly isolated OCC or OCC cultured 4 h in 300 μM 
dbcAMP with (AICAR) or without (Con) 1 mM AICAR (230 OCC per lane). Blots were stripped and 
reprobed with anti-ACC antibody as a loading control. (B) AMPK and pACC levels in freshly isolated DO 
or DO cultured 2 h in 300 μM dbcAMP with (AICAR) or without (Con) 500 μM AICAR. Only germinal 
vesicle (GV)-stage oocytes were collected and assayed (500 oocytes per lane). (C) DO were freshly 
isolated or cultured in 300 μM dbcAMP with (+) or without (−) AICAR (250 μM) for 1, 2, or 4 h (235 
oocytes per lane). All oocytes were at the GV stage, except for the 4 h AICAR-treated group, which 
contained only germinal vesicle breakdown (GVB)-stage oocytes. 
The experiments were repeated in DO. DO were cultured in 300 μM dbcAMP plus or minus AICAR for 2 
h, and only GV-stage oocytes were collected for analysis. For the above blot, extract from OCC was 
electrophoresed on a 3–8% Tris–Acetate gel, which produces distinct bands for pACC but more blurred 
bands for PT172. Initial attempts at using this gel for detection of PT172 in oocyte extracts proved 
unsuccessful; consequently, we carried out electrophoresis using a 4–12% Bis–Tris gel. Under these 
conditions, phosphorylation of Thr-172 on AMPK was detected in freshly isolated oocytes that 
decreased after 2 h of culture in dbcAMP alone but was increased by AICAR treatment (Fig. 2B). Ser-79 
phosphorylation on ACC showed the same pattern, but the bands were less distinct. That the 
phosphorylation of Ser-79 on ACC parallels that of Thr-172 on ACC confirms the usefulness of the anti-
pACC antibody as a marker of AMPK activity in mouse oocytes. The elevated phosphorylation of AMPK 
in the AICAR-treated GV-stage DO suggests that AMPK is activated prior to oocyte meiotic resumption, 
which supports the idea that AMPK triggers oocyte maturation. 
Using the anti-pACC antibody, a more detailed time course of AMPK activation by AICAR in DO was 
determined. DO were cultured in 300 μM dbcAMP with or without AICAR (250 μM) for 1, 2 or 4 h 
before probing extracts for AMPK activity with anti-pACC antibody. All oocytes used for analysis were 
at the germinal vesicle (GV) stage, except for the 4 h AICAR-treated group, which contained only 
germinal vesicle breakdown (GVB)-stage oocytes. For this and all subsequent pACC Western blotting, 
we utilized 3–8% Tris–Acetate gels. Results of the time course experiment show that AMPK is activated 
within 1 h of culture (Fig. 2C), well before the initiation of meiotic induction, which is not manifested 
until after 2 h of culture under these conditions (Downs et al., 2002). 
To directly measure AMPK activity in AICAR-treated GV-stage oocytes, SAMS peptide phosphorylation 
assays were performed. SAMS peptide is a peptide sequence based on the unique phosphorylation site 
(Ser-79) of ACC for AMPK and is a specific substrate for the kinase (Davies et al., 1989). Extracts were 
assayed from GV-stage fresh DO or from GV-stage DO cultured for 2 h in dbcAMP-containing medium 
in the presence or absence of AICAR. Fresh oocytes contained a high level of AMPK activity that was 
reduced by 86% after 2 h of culture under meiosis-arresting conditions (Fig. 3). In agreement with the 
results of Western blotting, AICAR increased the AMPK activity 3.4-fold (Fig. 3), thereby confirming that 
an increase in AMPK precedes GVB. 
 
Fig. 3. Effect of AICAR on AMPK activity in GV-stage oocytes. AMPK activity was analyzed in extracts 
from freshly isolated oocytes or from GV-stage oocytes after 2 h culture in 300 μM dbcAMP alone 
(Control) or dbcAMP plus 500 μM AICAR (+AICAR). A different letter denotes a significant difference. 
AMPK inhibitors block AMPK activation and AICAR-induced oocyte maturation 
Compound C, a potent small-molecule AMPK inhibitor (Zhou et al., 2001), was tested on AICAR-
induced oocyte maturation. DO were preincubated with increasing concentrations of compound C in 
dbcAMP-containing medium for 0.5 h before addition of 250 μM AICAR, and cultures were continued 
for 4 h before GVB assessment. A parallel group of DO was cultured 4.5 h in dbcAMP-supplemented 
medium containing increasing concentrations of compound C but without added AICAR. In the absence 
of AICAR, 34% of the control oocytes resumed maturation, and compound C exerted a modest 
inhibitory effect (Fig. 4A). AICAR treatment increased the maturation percentage to 83%, and this 
stimulation was dose-dependently eliminated by compound C. Inhibition was reversible as it was 
eliminated by washing out compound C and further culture in dbcAMP-free medium (data not shown). 
 
Fig. 4. Effects of compound C on AICAR-induced meiotic maturation and ACC phosphorylation. (A) DO 
were preincubated 0.5 h in medium containing 300 μm dbcAMP with or without increasing 
concentrations of compound C. AICAR was then added to some of the tubes, and cultures were 
continued for 4 h before assessment of GVB. (B) Western analysis of pACC in extracts of GV-stage DO 
(250 oocytes per lane). Extracts were prepared from GV-stage DO cultured 2 h in medium containing 
300 μM dbcAMP, dbcAMP plus AICAR (500 μM) or dbcAMP plus both AICAR and compound C (5 μM). 
The mean pACC/ACC ratio of two blots is shown in the corresponding graph, normalized to the 
dbcAMP alone control group. 
To assess the effect of compound C on AMPK activity in these oocytes, pACC levels were determined in 
GV-stage oocytes by Western blot analysis. After 2 h of culture, very little phosphorylation of ACC was 
detected in oocytes cultured in dbcAMP alone, but this was increased by AICAR treatment. Exposure of 
AICAR-treated oocytes to compound C significantly reduced phosphorylation of pACC, indicating 
suppression of AMPK activity within oocytes (Fig. 4B). 
To rule out the possibility of a general toxic effect, compound C was tested on okadaic acid (OA)-
induced oocyte maturation. DO were pre-treated with dbcAMP plus increasing concentrations of 
compound C for 0.5 h before adding OA, and GVB was assessed after 4 additional hours of culture. 
Compound C had no inhibitory effect on OA-induced oocyte maturation even at a concentration 10-
fold higher than that which effectively blocked AICAR-induced maturation (Fig. 5A). The kinetics of OA-
stimulated GVB was only slightly delayed by 5 μM compound C (data not shown). Extracts from GV-
stage oocytes after 1.5 h treatment with 1 μM OA revealed only a modest activation of AMPK when 
compared to AICAR-treated oocytes (Fig. 5B). These results show that compound C is not a non-specific 
inhibitor of maturation and indicate that AMPK activation is not the principal means by which OA 
stimulates meiotic resumption. 
 Fig. 5. Effects of compound C on okadaic-acid (OA)-induced meiotic resumption and ACC 
phosphorylation. (A) DO were preincubated with increasing concentrations of compound C for 0.5 h 
before adding 1 μM OA in 300 μM dbcAMP-containing medium. GVB percentage was assessed after 4 
h of culture. (B) Western analysis of pACC levels in OA-treated GV-stage oocytes (250 oocytes per 
lane). DO were treated in 300 μM dbcAMP containing medium with 1 μM OA or 500 μM AICAR for 1.5 
h. The mean pACC/ACC ratio of two blots is shown in the corresponding graph, normalized to the 
dbcAMP alone control group. 
AICAR is transported into cells via the adenosine transport system and is then phosphorylated by 
adenosine kinase to form the AMP analog, ZMP (Corton et al., 1995, Gadalla et al., 2004). To discount 
the possibility that compound C blocks AMPK activation by inhibition of AICAR transport into the 
oocytes or its conversion to ZMP, we tested the effect of compound C on: (1) the uptake of 
radiolabeled adenosine by mouse oocytes and (2) adenosine-stimulated ATP production in oocytes. To 
measure possible effects on AICAR uptake, DO were cultured 30 min in control medium or medium 
containing 2 mM uridine or increasing concentrations of compound C. Tritiated adenosine was then 
added, and cultures were continued for 3 h. Uridine served as a positive control for adenosine 
transport inhibition (Downs, 1999). Fig. 6 shows the mean of two experiments. Compound C did not 
affect the uptake of adenosine at concentrations that completely suppressed AICAR-induced 
maturation, while uridine totally eliminated uptake (Fig. 6A). To test compound C for an effect on 
adenosine kinase, DO were cultured for 3 h in control medium or medium containing 250 μM 
adenosine, in the presence or absence of compound C, and individual oocytes were then analyzed for 
ATP. As shown in Fig. 6B, adenosine stimulated an increase in ATP levels that was not affected by the 
presence of compound C. These data demonstrate that the ability of the oocyte to take up and convert 
AICAR to ZMP was not compromised by compound C. 
 
Fig. 6. Effects of compound C on adenosine uptake and adenosine phosphorylation in DO. (A) DO were 
cultured 30 min in control medium or medium containing 2 mM uridine or increasing concentrations of 
compound before the addition of tritiated adenosine and the continuation of culture for 3 h. Groups of 
25 oocytes were analyzed for radioactivity by scintillation spectroscopy (mean ± SEM of three 
experiments). (B) DO were cultured 3 h in control medium or medium containing 250 μM adenosine or 
adenosine plus 5 μM compound C. Individual oocytes were then analyzed for ATP. The number of 
oocytes assayed is given below each bar. An asterisk denotes a significant difference from the control 
group. 
Adenine 9-β-d-arabinofuranoside (araA) is the precursor of araATP, a competitive inhibitor of AMPK 
(Henin et al., 1996). We tested this inhibitor on AICAR-induced maturation to determine if it could 
duplicate the inhibitory action of compound C. Oocytes were pretreated with dbcAMP plus increasing 
concentrations of araA for 0.5 h before adding 250 μM AICAR, and GVB percentages were determined 
after 4 additional hours of culture. AICAR increased the maturation percentage from 20% to 80%, and 
this was blocked by araA in a dose-dependent fashion (Fig. 7A). Western analysis demonstrated an 
increased phosphorylation of ACC in response to AICAR that was suppressed by araA (Fig. 7B). 
 
Fig. 7. Effects of araA on AICAR-induced oocyte maturation and ACC phosphorylation. (A) DO were 
pretreated 0.5 h in 300 μM dbcAMP-supplemented medium with increasing doses of araA; 250 μM 
AICAR was then added, and cultures were continued for 4 h before assessment of GVB. A different 
letter denotes a significant difference. (B) Western analysis of pACC levels in araA and AICAR-treated 
GV-stage oocytes (250 oocytes per lane). DO were preincubated with 1 mM araA for 0.5 h in 300 μM 
dbcAMP before adding 500 μM AICAR, and cultures were continued for 2 h. The mean pACC/ACC ratio 
of two blots is shown in the corresponding graph, normalized to the dbcAMP control group. 
AICAR and its metabolites may have effects unrelated to AMPK activation (Kemp et al., 1999), and it 
was therefore important to consider alternative methods to stimulate the activity of the kinase and 
relate the activity to meiotic status. To accomplish this end, we utilized two additional strategies, (1) 
manipulation of adenosine metabolism and (2) treatment of oocytes with the anti-diabetic agent 
rosiglitazone. 
DCF plus adenosine induces oocyte maturation and AMPK activation 
Adenosine, a component of follicular fluid, exerts a meiosis-arresting action on oocytes (Eppig et al., 
1985, Miller and Behrman, 1986, Salustri et al., 1988, Downs, 1999). This nucleoside has two main 
metabolic routes within cells—phosphorylation by adenosine kinase to generate AMP and deamination 
by adenosine deaminase to produce inosine. Deoxycoformycin (DCF), an adenosine deaminase 
inhibitor, has no effect on oocyte maturation on its own but can reverse the inhibitory effect of 
adenosine in CEO (Downs, 1999, Downs et al., 2002). This led to the idea that blocking deamination of 
adenosine might divert increased adenosine through adenosine kinase, causing an accumulation of 
AMP, activation of AMPK and meiotic induction. 
We first tested the effects of DCF on adenosine-mediated meiotic arrest. DO were cultured for 17–18 h 
in medium containing 150 μM dbcAMP plus increasing concentrations of adenosine in the absence or 
presence of 250 μM DCF. This lower concentration of dbcAMP was used to achieve a suboptimal level 
of inhibition that would then be augmented by the addition of adenosine (cf. Downs, 1999), because 
adenosine alone has a very limited inhibitory effect. As shown in Fig. 8, adenosine dose-dependently 
suppressed oocyte maturation, while at each concentration DCF completely reversed this effect. A 
time course experiment showed that the meiotic induction brought about by DCF treatment was slow: 
a small increase in maturation was evident after 6 h of culture, with complete reversal achieved by 18 
h (Fig. 8B). 
 Fig. 8. DCF reversal of the inhibitory effect of adenosine on oocyte meiotic resumption. (A) DO were 
cultured in 150 μM dbcAMP or adenosine plus 250 μM DCF, with increasing concentrations of 
adenosine. After 17–18 h culture, oocytes were fixed and stained with Hoechst, and GVB was assessed 
under a fluorescent microscope. Groups with at least one identical letter are not significantly different. 
(B) Kinetics of DCF effects on adenosine-treated oocyte maturation. DO were cultured in 150 μM 
dbcAMP, dbcAMP plus 250 μM adenosine or dbcAMP plus adenosine and 250 μM DCF. Meiotic 
resumption was determined at the indicated times. (C) Western analysis of pACC in DCF-treated GV-
stage oocytes (250 oocytes per lane). DO were cultured 6 h in 150 μM dbcAMP, dbcAMP plus 250 μM 
adenosine or dbcAMP plus adenosine and 250 μM DCF. 
Western blot analysis was next performed to assess the phosphorylation of ACC in oocytes treated 
with or without DCF, in the presence of adenosine. GV-stage oocytes were collected after 6 h of 
treatment with adenosine alone or with adenosine plus DCF. Little phosphorylation of ACC was 
observed in the adenosine alone group, but significant phosphorylation was stimulated upon addition 
of DCF (Fig. 8C). 
To further clarify the effect of DCF on adenosine-treated oocytes, experiments were performed to 
measure oocyte AMP and ATP levels. In individual oocytes, ATP was measured in freshly isolated 
oocytes or oocytes cultured 5 h in control inhibitor-free medium or in medium containing adenosine 
alone, DCF alone or adenosine plus DCF. Fresh oocytes contained 3.55 mmol ATP per kg wet wt of 
oocyte, and this decreased to 2.5 mmol per kg after culture in control medium for 5 h (Fig. 9A). 
Adenosine or DCF alone had a modest stimulatory effect on ATP levels, but the combination of 
adenosine plus DCF profoundly increased ATP, even well above the levels observed in fresh oocytes. 
These results demonstrate that DCF treatment elicits a significant shift in adenosine metabolism 
towards phosphorylation. 
 Fig. 9. AMP/ATP levels in DCF- and adenosine-treated oocytes. (A) ATP was measured in fresh DO or 
DO cultured 3 h in control medium or medium containing 250 μM adenosine, 250 μM DCF or 
adenosine plus DCF. The number of oocytes assayed in each group is given below each bar. Groups 
with at least one identical letter are not significantly different. (B) AMP was measured in fresh oocytes 
or in oocytes cultured 3 or 5 h in control medium or in medium containing 250 μM adenosine, 250 μM 
DCF or dbcAMP plus DCF. The number of oocytes assayed per treatment group ranged from 31 to 40. 
AMP levels were next examined under the same culture conditions, with measurements taken at 0, 3 
and 5 h. These results are shown in Fig. 9B. Fresh oocytes contained 1.25 mmol AMP per kg wet wt of 
oocyte. In control medium or in medium containing adenosine or DCF alone, AMP remained 
unchanged or decreased after 3 and 5 h of culture. However, in the adenosine plus DCF group, AMP 
was significantly increased by 5 h. These results are consistent with AMP-induced activation of AMPK 
as the mechanism for the DCF-mediated reversal of adenosine-maintained meiotic arrest. 
Rosiglitazone-induced meiotic resumption and AMPK activation 
Rosiglitazone is an anti-diabetic agent that has recently been shown to activate AMPK by increasing the 
cellular AMP/ATP ratio (Fryer et al., 2002a). We therefore tested the effect of rosiglitazone on meiotic 
maturation and AMPK activation. Because preliminary attempts to treat dbcAMP-arrested oocytes 
with rosiglitazone produced inconsistent results on oocyte maturation, we report the actions of the 
drug on oocytes maintained in meiotic arrest with hypoxanthine. DO or CEO were cultured for 17–18 h 
in 4 mM hypoxanthine plus increasing concentrations of rosiglitazone before assessment of GVB. 
Although it did not affect oocyte maturation in CEO, rosiglitazone at 100 μM increased the frequency 
of meiotic resumption in DO from 61% to 79% (Fig. 10A). Higher concentrations of rosiglitazone were 
toxic to oocytes, increasing the level of cell death (data not shown) and inhibiting oocyte maturation. 
Western blot analysis revealed increased phosphorylation of ACC in GV-stage oocytes cultured for 2 h 
in 300 μM dbcAMP plus rosiglitazone compared to oocytes cultured in dbcAMP alone, with 
phosphorylation of ACC being greatest in the AICAR-treated oocytes (Fig. 10A). 
 
Fig. 10. Effects of rosiglitazone on meiotic resumption and ACC phosphorylation. (A) DO or CEO were 
cultured 17–18 h in 4 mM HX with increasing concentrations of rosiglitazone and then assessed for 
GVB. There was no significant difference between any of the CEO groups. Within the DO groups, a 
different letter denotes a significant difference. (B) Western analysis of GV-stage DO after 2 h of 
treatment with (Ros) or without (Con) 100 μM rosiglitazone (500 oocytes per lane). 500 μM AICAR-
treated oocytes were shown as a positive control. 
AMPK and spontaneous maturation 
Two types of experiments were carried out to test for possible AMPK involvement in spontaneous 
maturation. In the first experiment, DO were held in meiotic arrest for 0.5 h with 300 μM dbcAMP in 
the presence or absence of 5 μM compound C. Oocytes were then washed free of dbcAMP, and 
cultures were continued for varying periods of time. As shown in Fig. 11A, compound C produced a 
significant delay in oocyte maturation. To determine if AMPK is activated in spontaneously maturing 
oocytes prior to GVB, DO were maintained in meiotic arrest with dbcAMP for 2 h, after which they 
were split into two groups, one remaining in dbcAMP for 0.5 h and the other washed free of dbcAMP 
and cultured for 0.5 h in control inhibitor-free medium. The 2-h preincubation assured a drop in 
phosphorylated ACC from fresh levels before the release from dbcAMP arrest. Extracts from GV-stage 
oocytes were then processed for pACC Western analysis. When oocytes were maintained in meiotic 
arrest for 2.5 h, very little phosphorylation of ACC was detected, whereas oocytes cultured in the 
absence of dbcAMP for the last 0.5 h exhibited a prominent pACC band, indicating active AMPK (Fig. 
11B). 
 
Fig. 11. AMPK involvement in spontaneous maturation. (A) DO were cultured 0.5 h in medium 
containing 300 μM dbcAMP with or without 5 μM compound C. They were then washed free of 
dbcAMP and cultured for varying periods up to 3 h in the presence or absence of 5 μM compound C 
before assessment of GVB. (B) Western analysis of GV-stage DO after 2 h preincubation in 300 μm 
dbcAMP followed by either 0.5 h in dbcAMP (+dbc) or 0.5 h in inhibitor-free control medium (−dbc) 
(250 oocytes per lane). 
Discussion 
In the present study, we present results that strongly support a causal role for AMPK in meiotic 
maturation. The new evidence may be summarized as follows: 
(1) Microinjection of constitutively active, but not catalytically inactive, kinase into dbcAMP-arrested 
oocytes stimulated GVB. 
(2) Both Western blot analysis and kinase assays indicated that AMPK activity was increased in AICAR-
treated oocytes prior to meiotic resumption. 
(3) Compound C and araA, two pharmacological inhibitors of AMPK, blocked AICAR-induced oocyte 
meiotic resumption and decreased the activity of AMPK in AICAR-treated, GV-stage oocytes, as judged 
by phosphorylation of ACC. 
(4) Activation of AMPK by two additional means, i.e., rosiglitazone or adenosine plus DCF, also 
triggered meiotic maturation. 
(5) AMPK activity increased prior to GVB in spontaneously maturing oocytes; moreover, compound C 
transiently blocked spontaneous maturation. 
Eliciting GVB by microinjection of active, but not inactive, AMPK catalytic subunit demonstrates that 
AMPK can directly stimulate meiotic resumption. In these experiments, we used a constitutively active 
(T172D) mutant that would not be sensitive to the protein phosphatases that would be present in the 
oocytes. Microinjection of active kinase stimulated an increase in GVB of about 20%, while the meiotic 
induction achieved by AICAR was much higher. There could be a number of reasons why stimulation of 
GVB by active kinase may be limited compared with the effects of AICAR. For example, only the kinase 
domain of the α1 subunit was injected. The α1 and α2 isoforms appear to have rather similar 
specificity in solution (Woods et al., 1996), but the kinase domain represents only about 25% of the 
total sequence of an αβγ hetertrimer, and the α1 kinase domain may lack targeting sequences that 
direct the kinase to the substrate required for the effect on oocyte maturation. Despite the limited size 
of the effect, the ability of constitutively active AMPK to stimulate meiotic resumption strongly 
supports a positive role for the kinase in meiosis. In a previous study, we showed that AICAR, known to 
be a potent activator of AMPK in somatic cells, stimulated meiotic resumption and AMPK activation in 
mouse oocytes (Downs et al., 2002). In the present study, we provide evidence that the ability of AICAR 
to stimulate maturation is due to AMPK activation. Using both anti-PT172 and anti-pACC antibodies as 
probes, Western blot analysis revealed that AMPK was activated at the GV stage by AICAR, and this 
was confirmed by AMPK kinase assays using the SAMS peptide as substrate. While GVB is initiated by 
AICAR after more than 2 h of culture (Downs et al., 2002), AMPK is already activated within 1 h. Thus, 
AMPK activation precedes GVB, a finding consistent with its function as a meiotic inducer. 
Further evidence supporting a causal role for AMPK in meiotic resumption was provided by 
experiments with inhibitors. Compound C was the first potent and selective inhibitor of AMPK to be 
described (Zhou et al., 2001), while araA, a precursor of araATP, has also been shown to competitively 
suppress AMPK activity (Henin et al., 1996). Both inhibitors blocked AICAR-induced maturation in a 
dose-dependent fashion and prevented AMPK activation as assessed by phosphorylation of ACC. While 
the specificity of these inhibitors for AMPK may not be absolute, their ability to block both AICAR-
induced maturation and AMPK activation, despite the fact that they inhibit AMPK via different 
mechanisms, lends credence to the idea that AMPK is a meiotic inducer. 
One point of concern for compound C was the possibility that it might act by preventing AICAR uptake 
and accumulation of ZMP (Fryer et al., 2002a, Fryer et al., 2002b). Since AICAR is an adenosine analog, 
we tested the effects of compound C on adenosine uptake and its metabolism to ATP. Neither uptake 
of adenosine nor its stimulation of ATP production was adversely affected by compound C, thereby 
discounting a negative influence in ZMP generation. It should also be noted that compound C 
completely blocked meiotic induction by three different stresses, none of which involved metabolic 
processing of exogenous nucleoside (LaRosa and Downs, in press). 
To determine if compound C exerts a non-specific inhibitory influence on meiosis, we tested its effect 
on okadaic acid (OA)-induced maturation. OA is an inhibitor of protein phosphatase 1 and 2A that has 
been shown to stimulate oocyte maturation in many species (Alexandre et al., 1991, Gavin et al., 1991, 
Schwartz and Schultz, 1991). Recent work shows that protein phosphatase 1 is the OA-sensitive protein 
phosphatase important in the regulation of the acquisition of meiotic competence, nuclear events 
during meiotic arrest and GVB in mouse oocytes (Wang et al., 2004). OA is involved in regulation of 
protein kinase B (PKB) activity, which plays a role in CDK1 activation and meiotic resumption in mouse 
oocytes (Kalous et al., 1999). In mouse oocytes, OA is a potent inducer of meiosis, stimulating GVB 
within 1.5 h in dbcAMP-arrested oocytes, with induction completed by 3 h (LaRosa and Downs, 2005). 
In this study, compound C had no inhibitory effect on OA-induced maturation during overnight culture, 
and only marginally attenuated the kinetics of OA-induced maturation, thereby demonstrating 
specificity in the inhibitory actions of the drug. Moreover, Western blot analysis revealed that, 
although GV-stage oocytes after 1.5 h of OA treatment contained relatively higher amounts of 
phosphorylated ACC compared to control oocytes cultured in dbcAMP alone, these levels were still 
lower than in AICAR-treated oocytes. These results provide evidence that OA treatment may lead to 
some degree of AMPK activation but that such activation is not necessary for OA-induced maturation. 
Despite AICAR serving as an effective stimulator of both AMPK activation and meiotic maturation, it 
remained possible that it could influence meiosis by means unrelated to AMPK activation (Kemp et al., 
1999). It was therefore important to employ additional strategies for generating active kinase and 
relating that activity to meiotic status. To achieve this, we utilized two different treatments: (1) 
adenosine plus DCF and (2) rosiglitazone. DCF, a potent adenosine deaminase inhibitor, reversed the 
inhibitory effect of adenosine on oocyte maturation in CEO (Downs, 1999, Downs et al., 2002). We 
hypothesized that, by blocking adenosine deaminase, adenosine metabolism was diverted towards 
phosphorylation, resulting in AMP accumulation, activation of AMPK and meiotic induction (Downs et 
al., 2002). In the present study, we confirmed that there was a stimulatory action of DCF on oocyte 
maturation and showed that AMPK activity was, indeed, high prior to GVB. It was also shown that DCF 
caused a diversion of adenosine towards the phosphorylation pathway and a subsequent accumulation 
of adenyl nucleotides. A buildup of oocyte AMP in the presence of DCF was consistent with activation 
of AMPK and stimulation of GVB. Interestingly, increases in both AMP and ATP were observed in 
oocytes treated with adenosine and DCF. However, as the affinity of the CBS domains on the γ subunit 
for AMP is higher than that for ATP (Scott et al., 2004), a small increase in AMP should displace the ATP 
and increase the kinase activity. We propose that the elevated AMP in oocytes is sufficient to 
overcome the inhibitory effect of ATP on AMPK. Whether alterations in oocyte AMP levels normally 
contribute to the signal triggering meiotic resumption in vivo remains to be determined. 
We also tested the effect of the anti-diabetic thiazolidinedione drug rosiglitazone on oocyte 
maturation and AMPK activation. This drug is an inhibitor of complex I of the respiratory chain 
(Brunmair et al., 2004) and has been reported to increase the AMP/ATP ratio with concomitant 
activation of AMPK in a muscle cell line (Fryer et al., 2002a). Rosiglitazone produced a small, but 
significant, increase in GVB in HX-arrested DO, whereas it had no effect on meiotic induction in CEO. 
The poor potency of rosiglitazone in meiotic induction when compared to AICAR may be due to a 
weaker stimulation of AMPK in mouse oocytes since GV-stage oocytes after 2 h of treatment with 
rosiglitazone exhibited less intense phosphorylation of ACC than AICAR-treated oocytes. It should also 
be noted that rosiglitazone at high concentrations is toxic to oocytes. We suspect that this may be due 
to a reduction of ATP concentrations below the threshold required to maintain oocyte viability. Thus, 
there appears to be a narrow window of rosiglitazone concentrations in which a small drop in ATP 
leads to a weak activation of AMPK and a small effect on GVB but that at higher concentrations any 
effect on meiotic resumption is prevented by loss of viability. 
Surprisingly, freshly isolated DO or OCC contained a high level of phosphorylation of AMPK on Thr-172 
and ACC on Ser-79, indicating a high AMPK activity, and this was confirmed by directly assaying oocyte 
extracts for AMPK activity. However, this activity was greatly reduced within 1 h of culture. AMPK is a 
stress-activated enzyme, and even gentle physical manipulation can stimulate the kinase (Hardie et al., 
2000a, Hardie et al., 2000b). It therefore seems likely that the process of oocyte isolation, involving 
ovary manipulation, piercing follicles with needles, oocyte denudation and pipetting could contribute 
to the high level of active AMPK in fresh oocytes. Yet, we cannot discount the possibility that oocyte 
AMPK activity is high at the time of isolation and that AICAR and the other meiosis-inducing stimuli 
used in this study act to maintain an already active kinase. Work is in progress to address this issue. 
Two lines of evidence suggest that AMPK is involved also in spontaneous maturation. First, compound 
C suppressed spontaneous GVB at a concentration that was also effective on meiotic induction; 
second, AMPK activity increased prior to GVB in spontaneously maturing DO, as indicated by pACC 
Western analysis. While these results support the participation of AMPK, they do not establish whether 
AMPK activity is essential for spontaneous maturation, particularly since the arrest by compound C was 
transient. 
The primary purpose of the present study was to establish whether AMPK can stimulate meiotic 
resumption in mouse oocytes. Although the methods employed to activate AMPK may not have 
mimicked signals occurring in vivo, the results nevertheless provide compelling evidence that AMPK is 
a potent inducer of maturation. Current research is aimed at determining what physiological role, if 
any, AMPK plays in the control of oocyte maturation. Although the data indicate involvement in both 
spontaneous maturation and meiotic induction, the necessity for AMPK participation in meiotic 
regulation remains to be demonstrated. 
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